VolitionRX Ltd
VNRX
$0.59
Closing
▼-4.18%
1D
▼-17.14%
YTD
Market cap
$48.76M
52 week high
$2.08
52 week low
$0.55
Volume
30,688
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$48.76M
Analysts' Rating
BUY
Price Target (Mean)
3.7625
Total Analysts
5
P/E
Operating Margin
-5237.61%
Beta
1.39
Revenue Growth (Annual)
240.30%
52 week high
$2.08
52 week low
$0.55
Div. Yield
%
EPS Annual Growth
-21.43
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
VolitionRx Limited is a multi-national epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop blood tests to help diagnose and monitor a range of diseases, including certain cancers and diseases associated with NETosis, such as sepsis and COVID-19. The Company’s tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluids. Its Nucleosomics technology uses chromosomal structures called nucleosomes as biomarkers in cancer and other diseases. Its key pillars include Nu.Q Cancer , Nu.Q NETs, Nu.Q Capture, Nu.Q Discover and Nu.Q Vet. Its Nu.Q family of tests acts as an early warning system by monitoring treatment response, disease progression and remission. Its Nu.Q tests use epigenetic information from tumor cells nucleosomes that helps physicians select the treatment for each patient, monitor their response and disease progression.
